期刊文献+

肝移植术后期主要死亡原因分析 被引量:8

Analysis of causes of late mortality in liver transplant recipients
原文传递
导出
摘要 目的研究肝移植术后期的死亡率和主要死亡原因, 探讨肝移植术后期导致死亡的主要并发症的风险因素、预防和治疗.方法回顾性地研究1981年2月至1998年4月进行的生存期大于1年的2940例肝移植长期随访结果, 着重分析其主要死亡原因与相关因素.结果肝移植术后第1~10年死亡率依次为20.4%,6.7%,4.5%,3.8%,3.7%、4.6%,3.5%,3.3%,2.9%,1.9%.后期死亡817例,主要原因依次为恶性肿瘤(复发+新生;20.69%)、心血管并发症(11.38%)、各种感染(11.26%)和呼吸系统并发症(9.42%).结论肝移植术后期主要死亡原因为复发或新生恶性肿瘤、心血管并发症、各种感染和呼吸系统并发症.尽早预防和及时治疗这些并发症,成为进一步提高肝移植长期生存率的关键. Objective To evaluate the rate and the cause of late mortality in liver transplant recipients and to compare the cause of death in relation to age, gender and diagnosis and year of transplantation. To study the prevention and management of these complications. Methods 2940 patients who underwent liver transplantation and survived more than 1 year between February 1981 and April 1998 were included in this analysis and were followed up to March 2000. Results The rate of death of 1-10 year is 20.4%,6.7%、4.5%、3.8%、3.7%、4.6%、3.5%、3.3%、2.9%、1.9%, respectively. 817 patients who survived more than 1 year have died during the follow-up period. The cause of death are shown that recurrent or de novo cancers has remained the most common cause of late mortality, comprising 20.69% of the deaths. This was follow with cardiovascular 11.38%, infection 11.26%, and respiratory 9.42% cause. Conclusion Recurrent or de novo cancers is the most common cause of late mortality. This was follow with cardiovascular liver transplantation, we are beginning to face these complications as the preeminent factor that will ultimately determine patient survival.
出处 《中华肝胆外科杂志》 CAS CSCD 2005年第4期244-247,共4页 Chinese Journal of Hepatobiliary Surgery
  • 相关文献

参考文献15

  • 1朱岳,江春平,John J. Fung,Ashok Jain.再次肝移植——挽救肝移植失败受体生命唯一的手段(附774例报告)[J].中华肝胆外科杂志,2002,8(11):646-649. 被引量:14
  • 2Sudan DL, Shaw BW Jr, Langnas AN, et al. Causes of late mortality in pediatric liver transplant recipients. Ann Surg, 1998, 227:289-295.
  • 3Rabkin JM, Melena L. Late mortality after orthotopic liver transplantation. Am J Surg,2001,181:475-479.
  • 4Sheil AG, Disney AP, Mathew TH, et al. Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transplant Proc,1997,29:825-827.
  • 5Jain A, Yee L, Nalesnik MA, et al. Comparative incidence of de novo nonloymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result date. Transplantation, 1998,66:1193-1200.
  • 6Jain A, Di-Martini A, Kashyap R, et al. Long-term follow-up after transplantation for alcoholic liver disease under tacrolimus. Transplantation, 2000, 70, 1335-1342.
  • 7Hojo M, Morimoto T,Maluccio M, et al.Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature, 1999,397:530-534.
  • 8Kauffman HM, Cherikh WS, Cheng Y. Posttransplantation malignancies: a problem, a challenge, and an opportunity. Liver Transpl, 2002, 8:488-490.
  • 9Pruthi J, Medkiff KA, Esrason KT,et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl, 2001,7:811-815.
  • 10Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl, 2001,7:S109-S118.

二级参考文献9

  • 1Jaurrieta E, Casais L, Figueras J,et al. Analysis of 500 liver transplantation at Bellvitage Hospital, Spain. Med Clin,2000,115: 521-523.
  • 2Lerut J, Laterre PE, Roggen F, et al. Adult hepatic retransplantation, UCLexperience. Acta Gastroenterol Belg, 1999,62: 261-266.
  • 3De Carlis L, Slim AO, Giacomoni A, et al. Liver retransplanta tion: indications andresult over a 15 year experience. Transplan tation, 2001,71: 90-95.
  • 4Grande L, Matus D, Rimola A, et al. Expanded liver donor age over 60 years forhepatic transplantation. Clin Transpl, 1998,12:297-301.
  • 5Gregory T. Everson, Igal Kam. Immediate postoperative care.In: Willis C, Maddrey ,Engene R. Schiff, eds. Transplantation of the liver. 3rd. ed. Philadelphia: LippincoteWilliams & Wilkins. 2000. 131-162.
  • 6Zulke C, Anthuber M, Kramling HJ, et al. Primary shunt perfusion detected by colourflow Doppler imaging and its impact on liver allograft survival. Clin Transpl,1997,11:163-168.
  • 7Kim WR, Wiesner RH, Poterucha JJ, et al. Hepatic retransplantation in cholestaticliver disease. Hepatology, 1999, 30: 395-400.
  • 8Pares D, Figueras J, Fabregat J, et al. Liver retransplantation in adults.Gastroenterology, 1999,116: 329-334.
  • 9Markmann JF, Markowitz JS, Yersiz H, et al. Long-term survival afterretransplantation of the liver. Ann Surg, 1997, 226:408-418.

共引文献14

同被引文献60

  • 1鞠卫强,何晓顺,朱晓峰,马毅,王东平,钱世鹍,巫林伟,叶勇,黄洁夫.肝移植术后心血管系统并发症的防治[J].中国现代手术学杂志,2004,8(6):335-338. 被引量:9
  • 2王德盛,宋振顺,窦科峰,刘正才,冯全兴,李韧,王群毅,王玉同,李剑平.终末期肝病评分系统用于评价肝移植患者的预后[J].中华普通外科杂志,2005,20(8):477-479. 被引量:5
  • 3沈中阳,陈宝公,江涛,谷川.一例成功的肝移植[J].中华器官移植杂志,1996,17(1):25-27. 被引量:13
  • 4Dec GW,Kondo N,Farrell ML,et al.Cardiovascular complication following liver transplantation.Clin Transplant,1995,9:463-471.
  • 5Gaskari SA,Honar H,Lee SS.Therapy insight:cirrhotic cardiomyopathy.Nat Clin Pract Gastroenterol Hepatol,2006,3:329-337.
  • 6Martinez-Rey C,Otero-Anton E,Tome S,et al.Circadian variability of blood pressure in liver transplant recipient without antihypertensive therapy.Transplant Proc,2005,37:1515-1516.
  • 7Neal DA,Brown MJ,Wilkinson IB,et al.Mechanism of hypertension alter liver transplantation.Transplantation,2005,79:935-940.
  • 8Stahl RL,Danean A,Hooks MA,et al.A hypereoagulable state follows orthotopic liver transplantation.Hepatology,1990,12(3Pt1):553-558.
  • 9Bal JS,Thuluvath PJ.Prolongation of QTc interval relationship with etiology and severity of liver disease,mortality and liver transplantation.Liver Int,2003,23.-243-248.
  • 10国际肝移植协会2008年香港会议.中国肝移植注册报告.https://www.cltr.org.

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部